Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) may be performed to treat a variety of malignant and nonmalignant disorders by eradicating tumor, replacing a non-functioning with a normal immune system, or replenishing a deficient enzyme. While HSCT may provide cure for many patients, barriers such as acute and chronic graft-versus-host disease (a/cGVHD) and graft failure continue to challenge clinicians with considerable potential for morbidity and mortality. A thorough understanding of each disease process is essential to the development of both pharmacologic and non-pharmacologic therapies in this setting; unfortunately, acute and chronic GVHD, are distinct, complex entities, and medications used to prevent and treat them cause significant toxicities and leave patients at high risk for overwhelming infections. Standard pharmacologic therapies that are currently in use are limited in that they have the potential to cause significant toxicity without completely curing the disease. Novel, non-pharmacologic therapies for the prevention and treatment of acute and chronic GVHD must continue to be developed and studied in randomized trials. Given that the potential mechanisms of action of the non-pharmacologic therapies discussed herein attempt to modulate the cellular milieu that supports the development of GVHD, a brief discussion of GVHD and its pathophysiology is warranted; detailed discussions are provided by Cutler et al. and Bolanos-Meade elsewhere in the current issue. We will therefore focus on two non-pharmacological innovative forms of therapy, and potentially, prevention of GVHD.
Keywords: Hematopoietic Stem Cell Transplantation (HSCT), immune system, chronic graft, host disease, Novel, non-pharmacologic therapies
Current Pharmaceutical Design
Title: Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Volume: 14 Issue: 20
Author(s): Jennifer Schneiderman
Affiliation:
Keywords: Hematopoietic Stem Cell Transplantation (HSCT), immune system, chronic graft, host disease, Novel, non-pharmacologic therapies
Abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) may be performed to treat a variety of malignant and nonmalignant disorders by eradicating tumor, replacing a non-functioning with a normal immune system, or replenishing a deficient enzyme. While HSCT may provide cure for many patients, barriers such as acute and chronic graft-versus-host disease (a/cGVHD) and graft failure continue to challenge clinicians with considerable potential for morbidity and mortality. A thorough understanding of each disease process is essential to the development of both pharmacologic and non-pharmacologic therapies in this setting; unfortunately, acute and chronic GVHD, are distinct, complex entities, and medications used to prevent and treat them cause significant toxicities and leave patients at high risk for overwhelming infections. Standard pharmacologic therapies that are currently in use are limited in that they have the potential to cause significant toxicity without completely curing the disease. Novel, non-pharmacologic therapies for the prevention and treatment of acute and chronic GVHD must continue to be developed and studied in randomized trials. Given that the potential mechanisms of action of the non-pharmacologic therapies discussed herein attempt to modulate the cellular milieu that supports the development of GVHD, a brief discussion of GVHD and its pathophysiology is warranted; detailed discussions are provided by Cutler et al. and Bolanos-Meade elsewhere in the current issue. We will therefore focus on two non-pharmacological innovative forms of therapy, and potentially, prevention of GVHD.
Export Options
About this article
Cite this article as:
Schneiderman Jennifer, Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation, Current Pharmaceutical Design 2008; 14 (20) . https://dx.doi.org/10.2174/138161208785061418
DOI https://dx.doi.org/10.2174/138161208785061418 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Cardiolipin Metabolism and the Role it Plays in Heart Failure and Mitochondrial Supercomplex Formation
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Circulating miRNAs in Successful and Unsuccessful Aging. A Mini-review
Current Pharmaceutical Design Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb
Current Medicinal Chemistry Etiologic Aspects of Pagets Disease of Bone
Current Rheumatology Reviews Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Preoperative Albumin Level Serves as a Predictor for Postoperative Pulmonary Complications Following Elective Laparoscopic Gastrectomy
Current Pharmaceutical Design Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus
Current Diabetes Reviews Cardiovascular Disease: From Diagnosis to Therapy
Current Medicinal Chemistry Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry